Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
We send one confirmation email first. Only emails about NTLA, unsubscribe in one click. Privacy
| PDUFA Date | Drug | Indication | Type | PoA |
|---|---|---|---|---|
| 2027-03-10 | — | BLA | 64% |
PoA = estimated probability of approval: base rates calibrated against BioRadar's verified FDA outcomes, adjusted for application type, modality, therapy area and cash runway. Not investment advice. See the full PDUFA calendar →
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
| Drug | Indication | Most advanced trial | Status |
|---|---|---|---|
| Lipid Nanoparticle Encapsulating mRNA En | Neuromuscular Disease | Phase 3 · NCT06672237 | Recruiting |
| NTLA-2002 | Hereditary Angioedema | Phase 3 · NCT06634420 | Active not recruiting |
| Biological NTLA-2002 | Hereditary Angioedema | Phase 1/2 · NCT05120830 | Active not recruiting |
| Biological NTLA-3001 | Lung Disease | Phase 1/2 · NCT06622668 | Withdrawn |
| LNP1265 | Hemophilia B | Phase 1/2 · NCT06379789 | Recruiting |
| REGV131 | Hemophilia B | Phase 1/2 · NCT06379789 | Recruiting |
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
NTLA holds $628.4M in cash and short-term investments (as of Jun 30, 2026) and burns about $100.2M/quarter from operations, an estimated runway of 18.8 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure: 50 · Elevated
Outlook Based on our research and development plans and our expectations related to the progress of our programs, we expect that our cash, cash equivalents and marketable securities as of June 30, 2026, the net proceeds from our April 2026 equity offering, as well as research and cost reimbursement funding from our col10-Q, Aug 2026
Recent financing filings on SEC EDGAR:
Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when NTLA files for a raise →
| Holder | Type | Shares | % of shares | As of |
|---|---|---|---|---|
| Blackrock Inc. | Institution (13F) | 15,409,023 | 11.00% | 2026-06-30 |
| ARK Investment Management LLC | Institution (13G, 5%+) | 14,207,324 | 10.14% | 2025-12-31 |
| STATE STREET CORPORATION | Institution (13G, 5%+) | 9,234,987 | 6.59% | 2026-06-30 |
| Shaw D.E. & Co., Inc. | Institution (13F) | 6,443,323 | 4.60% | 2026-06-30 |
| Vanguard Portfolio Management | Institution (13G, 5%+) | 6,266,007 | 4.47% | 2026-03-31 |
| Vanguard Capital Management | Institution (13G, 5%+) | 5,945,571 | 4.24% | 2026-03-31 |
| Two Sigma Investments, LP | Institution (13F) | 5,235,348 | 3.74% | 2026-06-30 |
| FMR, LLC | Institution (13F) | 4,773,034 | 3.41% | 2026-06-30 |
| RA Capital Management, L.P. | Institution (13F) | 4,526,926 | 3.23% | 2026-06-30 |
| Regeneron Pharmaceuticals Inc | Institution (13F) | 3,702,995 | 2.64% | 2026-06-30 |
| John M Leonard President and CEO, Director · +225,400 options |
Insider | 1,205,479 | 0.86% | 2026-08-20 |
| Fred E Cohen Director · +13,300 options |
Insider | 216,653 | 0.15% | 2026-06-09 |
Share count 140,126,693 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest (13F quarter ending 2026-06-30). Sources have different dates, so the split is approximate. Source: SEC EDGAR.
| Trade date | Insider | Transaction | Shares | Price | Owned after |
|---|---|---|---|---|---|
| 2026-08-21 filed 2026-08-24 |
LEONARD JOHN M |
Sale (S) | 2,785 | $13.00 | 1,147,064 |
| 2026-08-20 filed 2026-08-24 |
LEONARD JOHN M |
Sale (S) | 19,890 | $12.60 | 1,149,849 |
| 2026-07-22 filed 2026-07-24 |
Dulac Edward J III |
Sale (S) | 8,111 | $11.25 | 148,175 |
| 2026-07-02 filed 2026-07-06 |
Dulac Edward J III |
Sale (S) | 4,677 | $18.00 | 156,286 |
| 2026-07-01 filed 2026-07-06 |
Dube Michael P |
Sale (S) | 2,641 | $16.78 | 66,886 |
Only open-market purchases (P) and sales (S) are trading decisions. Awards (A), option exercises (M) and tax withholding (F) are compensation mechanics. Source: SEC Form 4.
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for NTLA and every other ticker you follow. Card required, cancel anytime.
Start 7-day free trial →